Theralase Technologies Inc. V.TLT

The ones we don't have!

[Pandora]

A breast cancer drug company GLSI Greenwich LifeSciences closed yesterday at $5.29 and opened this morning at $12 before running as high as $158 and then closing at $57. It is now up about $22.50 to $79.50 after hours.

Shares of Greenwich LifeSciences Inc. blasted 2,399.3% higher in very active and volatile afternoon trading Wednesday, after the Texas-based biopharmaceutical company displayed upbeat results of a Phase IIb trial for its breast cancer treatment. The stock, which has been halted no less than 20 times for volatility, was easily the biggest gainer trading on major U.S. exchanges, while trading volume of 15.9 million shares was many multiples of the full-day average of about 22,000 shares. The company said before the open that a poster presentation of five-year data for the GP2 clinical trial met all of its endpoints and showed zero recurrence of breast cancer in patients who had previously undergone surgery. The stock, which went public on Sept. 25, was now trading 2,159.7% above its $5.75 initial public offering price.

[tamarindo1]

And I missed it.

[StevenBirch]

I don't know if my heart could take that kind of action but I'd like to find out.

[ScienceFirst]

Exceptional medical results. Statistically significant Phase IIb clinical trial data shows that after median 5 years of follow-up, breast cancer patients treated with the GP2 immunotherapy had: No cancer recurrences if fully immunized No reported serious adverse events A well tolerated safety profile Greenwich LifeSciences plans to commence a Phase III clinical trial that is

[enriquesuave]

GLSI Market cap now at $686 Million. Hit a MC of about $2 billion at today's high.  When it's very clear that a drug will make it to market and be the next Gold Standard for an indication, MC adjusts quite quickly and stays there and grows over time. 

[Rumpl3StiltSkin]

First, we will probably not get this kind of action till we are on Nasdaq. Also, this is breast cancer, a very emotional play as well as the large number of those affected. So maybe we will trade like this once we are on Nasdaq and have NSCLC in the crosshairs. But I think we go much higher from here anyway, until then.

[tdon1229]

  Note that GLSI has a mere 12 million shares, as compared to Theralase's 202 million shares.  I'll leave the stock price comparisons as an exercise for investors.

[Rumpl3StiltSkin]

it settled last might at a market cap of 3/4 of $Billion, who knows where it will end up today. For TLT to end up at a MC of $750,000 would put SP at ~ $2 US. 

[Rumpl3StiltSkin]

Actually more like $2.50 US

[StevenBirch]

That would be a nice start.

[gojotv!]

Right?! And that's for a post-surgical, limited-to-breast-cancer drug! Now, look at Theralase's offering.... Most solid tumours... You go into the clinic or hospital, have an infusion of TLD-1433, shine a light or an Xray on it, and go home... and Buh-bye! Enjoy dinner with your family tonight. Call us back in 90 days for treatment #2... And THIS Phase 2 NMIBC (but soon to be so many more